REMARKS

5

Claims 1-5, 7-8 and new claim 9 are pending. The support in the published application for the amendments are as follows: Claim 1: deleting subject matter only; and Claim 9: claims 1 and 4. No new matter has been added.

Claims 1-5 are rejected under 35 U.S.C. 102(b) as being anticipated by Tomita, T. et al. (Rare Earths, 2002). (Office Action, page 2)

Claim 1 is amended to overcome Tomita by reciting a chemically distinct compound.

Tomita discloses an Eu(hfa-D)₃ BINAPO complex with R₂ as CF₃. In the claimed invention, however, R₂ cannot be CF₃ as claim 1 is amended in part as:

the groups included in (a), (b), and (c) may be substituted with an alkyl group of a halogen atom; and Ln represents a rare earth metal atom

Thus Tomita cannot now legally anticipate claims 1-5. It is respectfully requested that the rejection be withdrawn.

Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tomita, T. et al. (Rare Earths, 2002), in view of Alburger, J.R. (U.S. Patent 3,567,932). (Office Action, page 4)

Alburger discloses tris-(4,4,4-trifluoro-1-(2-thienyl)-1,3 butanediono)- europium, shown as:

$$\text{CF}_3$$

In the invention now claimed, the 2-thienyl group is eliminated from claim 1 by the amendment in part:

 (a) a cyclopentadienyl group (one CH₂ group existing in the cyclopentadienyl group may be replaced by -O- or -S-), Application No. 10/567,443 Amendment dated October 28, 2009 Reply to Office Action of August 7, 2009

Thus claims 1-6 are not at all taught by the combination of Tomita, discussed above, and Alburger. In other words, the combination of references nowhere teachs the distinct compounds now claimed.

It is respectfully requested that the rejection be reconsidered and withdrawn.

Claims 7 and 8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tomita, T. et al. (Rare Earths, 2002) and Alburger, J.R. (U.S. Patent 3,567,932)., as applied to claims 1-6 above, and in further view of Gladiali, S., et al., (Tetrahedron Asymmetry, 1998) and Norton T.R., et al., (U.S. Patent 2,723,982). (Office Action, page 6)

The amendments to claim 1 obviate the combination of Tomita, Alburger, Gladiali and Norton, for the reasons above, thus overcoming the rejection.

Furthermore, since none of the references disclose a Yb(hfa-D)₃ BINAPO complex, new claim 9 is neither anticipated or obvious.

In view of the above amendment, applicant believes the pending application is in condition for allowance.

In the event that this paper is not timely filed, Applicants respectfully petition for an appropriate extension of time. Please charge any fees for such an extension of time and any other fees which may be due with respect to this paper, to Deposit Account No. 04-1105.

Dated: October 28, 2009 Respectfully submitted,

Customer No. 21874 Electronic signature: /James E. Armstrong, IV/

James E. Armstrong, IV Registration No.: 42,266

EDWARDS ANGELL PALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205 (202) 478-7375

Attorneys/Agents For Applicant